EBI3 Antibody
Code | Size | Price |
---|
PSI-4967-0.02mg | 0.02mg | £150.00 |
Quantity:
PSI-4967-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Images
Documents
Further Information
Additional Names:
EBI3 Antibody: IL27B, IL-27B, IL27B, Interleukin-27 subunit beta, Epstein-Barr virus-induced gene 3 protein, IL-27 subunit beta
Application Note:
WB: 1-4 μg/mL; IF: 20 μg/mL ; IHC: 2.5 μg/mL;.
Antibody validated: Western Blot, Immunofluorescence, and Immunohistochemistry in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot, Immunofluorescence, and Immunohistochemistry in human samples. All other applications and species not yet tested.
Background:
EBI3 Antibody: EBI3 is a subunit in two distinct heterodimeric cytokines: interleukin-27 (IL-27) and IL-35. Like interleukin-23 (IL-23), IL-27 is a recently discovered member of the IL-6/IL-12 family of proinflammatory and immunoregulatory cytokines. It exists as a heterodimer composed of the p40-related protein EBI3 and an IL-12 p35-related protein termed p28. IL-27 is produced after activation by antigen-presenting cells and induces proliferation of na?ve but not memory CD4+ T-cells. It acts by binding to its receptor WSX-1 (also known as TCCR) and gp130 which results in the activation of a Jak/STAT signaling cascade, suggesting the IL-27 is involved in the regulation of immune processes. It has been suggested that IL-27 can also be used as a therapeutic agent against cancer as it can also induce tumor-specific anti-tumor activity mediated through CD8+ T-cells, IFN-gamma, and T-bet. IL-35 is composed of EBI3 and the p35 subunit of IL-12 and has been reported to have therapeutic effects against collagen-induced arthritis by expanding the population of regulatory T cells and suppressing Th17 cells. At least two isoform of EBI3 are known to exist.
Background References:
- Pfanz et al. Immunity2002; 16:779-90.
- Devergne et al. Proc. Natl. Acad. Sci. USA1997; 94:12041-6.
- Niedbala? et al. Eur. J. Immunol.2007; 3021-29.
- Pfanz et al. J. Immunol.2004; 172:2225-31.
Buffer:
EBI3 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Mouse: (46.7%), Rat: (46.7%)
Immunogen:
Anti-EBI-3 antibody (4967) was raised against a peptide corresponding to 16 amino acids near the carboxy?terminus of mature human EBI-3.
The immunogen is located within the last 50 amino acids of EBI3.
The immunogen is located within the last 50 amino acids of EBI3.
ISOFORMS:
Human EBI-3 has only 1 isoform (229aa, 25kD). Mouse EBI-3 has one isoform (228aa, 25kD) and rat EBI-3 also has one isoform (228aa, 25kD). 4967 can detect human EBI-3 but cannot detect mouse and rat EBI-3.
NCBI Gene ID #:
10148
NCBI Official Name:
Epstein-Barr virus induced 3
NCBI Official Symbol:
EBI3
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 25kD
Observed: 30 kD (25kD + 2 N-Glycosylations)
Observed: 30 kD (25kD + 2 N-Glycosylations)
Protein Accession #:
NP_005746
Protein GI Number:
14577917
Purification:
EBI3 Antibody is affinity chromatography purified via peptide column.
Research Area:
Immunology
Swissprot #:
Q14213
User NOte:
Optimal dilutions for each application to be determined by the researcher.
VALIDATION:
Recombinant Protein Test (Figure 2) shows that anti-EBI-3 antibody (4967) detects human recombinant IL-17 (IL-17A + IL-17B) protein that contains the amino acids of 4967 antigenic peptide.
Related Products
Product Name | Product Code | Supplier | EBI3 Peptide | PSI-4967P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|